Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2012

View Archived Issues

Ciclopiroxolamine evaluated in patients with hematological malignancies

Mouse model mimics characteristics of Tourette syndrome observed in patients

Soligenix acquires innate defense regulator

Neurocrine begins second phase IIb study of NBI-98854

Primary endpoint not met in phase III trial of L-BLP25 in NSCLC

iPSC-derived neurons as a model for AD treatment screening / News in Context

Japanese and U.S. group patents novel TRPV1 channel antagonists

Principia Biopharma discloses new protein kinase inhibitors

Gentium provides update on MAA for defibrotide

Arrowhead and Shire enter agreement to develop peptide-targeted therapeutics

MAA filed in Japan for additional pediatric indication of topiramate

Concert Pharmaceuticals synthesizes new deuterated CFTR activators

NewGen Therapeutics patents new agents for cancer

Novel antitumor metal complexes designed by Unitech

University of Toyama prepares new beta-carboline derivatives for cancer

IPI-145 well tolerated and active in patients with hematological malignancies

Researchers present clinical trial results on NOX-H94 for the treatment of ACD

Intercell obtains positive CHMP opinion for pediatric use of its JE vaccine

Amgen licenses rights to TAP technology for third cancer target

Allon Therapeutics' phase II/III trial of davunetide fails to show efficacy

UMN Pharma signs license agreement with Ildong Pharmaceutical for influenza vaccines

GlycoVaxyn and GSK enter collaboration to develop new bacterial vaccines

Idera Pharmaceuticals reports results from phase IIa IMO-3100 trial

Intercept Pharmaceuticals completes enrollment in phase III POISE Trial

MethylGene's phase II trial of MGCD-290 completes enrollment

Prana Biotechnology completes recruitment in Reach2HD study

BAY-80-6946 activity in non-Hodgkin's lymphoma leads to phase II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 22, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...